Clinical Trial Update: Treatment of Basal Cell Carcinomas With Methyl Aminolevulinate and Daylight [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating daylight-activated photodynamic therapy using methyl aminolevulinate for basal cell carcinomas; current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Basal Cell Carcinoma

Drugs mentioned

• Methyl aminolevulinate (methyl aminolevulinate)

Snippet

Sponsor: Bispebjerg Hospital | Conditions: Photodynamic Therapy, Basal Cell Carcinomas | Phase 2 | Status: UNKNOWN